A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors

Disease Sites:

Colon, Esophageal, Gastric/Gastroesophageal, Gastrointestinal, Lung, Non Small Cell, Pancreatic, Phase I, Rectal, Uterine

Staging:

Phase I

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

5FU bolus, 5FU continuous infusion, Cetuximab, Gemcitabine, Irinotecan, LY3962673, Leucovorin, Nab-Paclitaxel, Oxaliplatin

Principal Investigator(s):

Cardin, Dana

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

07-23-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTGIT24002P

National Clinical Trial ID:

NCT06586515

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available